相关临床试验
51
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
38
74.5%
终止
11
21.6%
撤回
2
3.9%
暂无批准数据
- Two Ludwig Princeton studies reveal that indigestible plant proteins, termed "proteins imitating fiber" (Prif), shift gut microbial metabolism away from harmful tyrosine-derived phenols toward healthful phenylalanine-derived metabolites. - Isotope-tracing experiments show beneficial phenols come almost entirely from dietary plant proteins, while harmful phenols arise from bacterial consumption of the host's own gut mucus lining. - A companion Nature Metabolism study demonstrates that mammalian metabolism independently produces many indole and phenol metabolites, challenging the assumption that these compounds originate solely from gut bacteria. - The findings have implications for designing dietary, probiotic, and therapeutic strategies to modulate microbiome-derived metabolites for disease prevention and treatment.
- A first-in-human phase 1 trial of Temferon, a gene therapy using patients' own engineered blood stem cells, met its safety primary endpoint in 24 patients with newly diagnosed, treatment-resistant glioblastoma. - The therapy reprograms the immunosuppressive tumor microenvironment by delivering interferon-α locally via tumor-infiltrating macrophages, avoiding the severe systemic toxicity that previously limited this cytokine's use. - Median overall survival reached 16.7 months in patients with unmethylated MGMT promoter, a population with among the worst prognosis, and two patients achieved late partial responses more than a year after treatment. - The study provides clinical proof-of-concept for a 'living drug' platform that could be applied to other solid tumors, with optimized versions already in development for ovarian cancer.
- Pilatus Biosciences announced FDA clearance of its IND application for PLT012, a first-in-class anti-CD36 monoclonal antibody targeting metabolic dysfunction in solid tumors. - PLT012 represents the first metabolic checkpoint therapy designed to reprogram the tumor microenvironment by blocking CD36-mediated lipid uptake and immune suppression. - The Phase 1 clinical trial is expected to begin in the first quarter of 2026, evaluating safety, tolerability, and preliminary efficacy in solid tumor patients. - Preclinical studies demonstrated PLT012's monotherapy activity across immune-hot and immune-cold tumors, with potential synergy when combined with PD-1/PD-L1 inhibitors.
- Pilatus Biosciences has been granted foundational patents in Europe and Australia for its novel CD36-targeted immunotherapy approach that modulates regulatory T cells to enhance anti-tumor immunity. - The patent covers the company's first-in-class antibody program targeting CD36, a metabolic checkpoint on regulatory T cells that suppresses immune responses in the tumor microenvironment. - This intellectual property milestone strengthens Pilatus' position in metabolic checkpoint immunotherapy, with their lead program PLT012 designed to reprogram the tumor microenvironment and restore anti-tumor immunity. - The announcement coincides with the 2025 Nobel Prize in Physiology or Medicine being awarded for discoveries in regulatory T cell biology, highlighting the field's growing importance.
- Researchers have developed a novel CAR-T cell therapy that can be controlled with existing oral drugs, offering an on/off switch for enhanced safety and efficacy. - The engineered CAR-T cells are activated by venetoclax to target cancer cells and deactivated by lenalidomide, both FDA-approved drugs. - Preclinical studies demonstrate the potential for improved safety and reduced T cell exhaustion, paving the way for clinical trials in solid tumors. - This innovative approach addresses challenges in treating solid tumors with CAR-T therapy by enabling remote control of CAR-T cell activity.
- Researchers have developed NeoDisc, an AI-enabled computational pipeline integrating multi-omics data for personalized cancer vaccine development. - NeoDisc identifies and prioritizes tumor-specific antigens, enhancing the accuracy of selecting effective targets for immunotherapies. - The pipeline addresses limitations in current methods by incorporating genomic, transcriptomic, and immunopeptidomic data. - NeoDisc is currently being used in Phase I clinical trials for personalized cancer vaccines and adoptive T cell therapies.
